Please provide your email address to receive an email when new articles are posted on . scPharmaceuticals Inc. announced the FDA approved its self-administered subcutaneous furosemide injection for ...
The FDA approved the first furosemide (Furoscix) formulation for subcutaneous self-administration by patients with congestive heart failure, scPharmaceuticals announced. The IV-equivalent formulation ...
Uncertainty regarding diuretic efficacy and optimal dosing in hemodialysis likely contributes to practice variation, according to investigators. A new study finds “substantial” variation in oral ...
The US Food and Drug Administration (FDA) has approved a furosemide preparation (Furoscix, scPharmaceuticals) intended for subcutaneous self-administration by outpatients with chronic heart failure ...
BURLINGTON, Mass., Oct. 10, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results